Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Terlipressin Administration in Septic Shock Refractory to Catecholamines

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by Assaf-Harofeh Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT00793559
First received: November 18, 2008
Last updated: NA
Last verified: November 2008
History: No changes posted

November 18, 2008
November 18, 2008
November 2008
July 2009   (final data collection date for primary outcome measure)
CI, SVR,HR,BP, noradrenalin administration,renal function [ Time Frame: 6 mo ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Terlipressin Administration in Septic Shock Refractory to Catecholamines
Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II

terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Septic Shock
  • Drug: terlipressin
    1 mg of terlipressin one time only
    Other Name: glypressin
  • Drug: terlipressin
    1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
  • Active Comparator: terlipressin bolus
    1 mg of terlipressin received one time only
    Intervention: Drug: terlipressin
  • Experimental: terlipressin drip
    Intervention: Drug: terlipressin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • septic shock patients receiving above 0.5 mcg/kg NA

Exclusion Criteria:

  • allergy to terlipressin, CHF, IHD, pregnancy
Both
18 Years to 90 Years
No
Contact: Tal Mann, Dr 97257345789 tal_mb@hotmail.com
Israel
 
NCT00793559
161/08
No
Dr Yuval Leonov, Assaf-Harofeh Medical Center
Assaf-Harofeh Medical Center
Not Provided
Study Director: Tal Mann, Dr Asaf Harofeh
Assaf-Harofeh Medical Center
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP